Pulmonary Drug Delivery Systems Market By Route of Administration/Delivery Platform (Inhalers, Metered-Dose Inhalers, Dry Powder Inhalers, Nebulizers, Soft Mist Inhalers); By Drug Class (SABA, ICS, LABA/LAMA, ICS/LABA, ICS/LABA/LAMA, Inhaled Antibiotics, Inhaled Pulmonary Hypertension Drugs, Mucolytics & Hypertonic Saline, Systemic Inhaled Therapies); By Application (Asthma, COPD, Cystic Fibrosis, Bronchiectasis, Pulmonary Arterial Hypertension, Pulmonary Hypertension Associated with ILD, Diabetes, Neurology, Infectious Diseases); By End User (Hospitals, Homecare Settings, Retail Pharmacies & Online Pharmacies, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Pulmonary Drug Delivery Systems Market: Respiratory Disease Volume, Specialty Inhaled Drugs, PAH Dry Powders, Inhaled Insulin, and Low-GWP Reformulation Expand Lung-Based Therapy

The Global Pulmonary Drug Delivery Systems Market is projected to grow at a CAGR of 7.2%, expanding from USD 58.7 billion in 2025 to USD 95.5 billion by 2032.

 

The Pulmonary Drug Delivery Systems Market is evolving from a traditional inhaler and nebulizer category into a broader drug-device platform. Asthma and COPD remain the largest prescription base, but the market is expanding into cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, diabetes, Parkinson’s disease, and difficult-to-treat lung infections. The market includes metered-dose inhalers, dry powder inhalers, nebulizers, soft mist inhalers, inhalation powders, inhalation suspensions, aerosol solutions, smart inhalers, spacer/chamber accessories, and high-payload pulmonary systems.

 

The underlying market dynamic is well defined. High-prevalence respiratory conditions support sustained, repeat inhaler utilization, while specialty inhaled therapies drive higher-value growth through advanced formulations, differentiated device platforms, and indication-specific delivery approaches. Future growth will depend on solutions that integrate clinical need, patient adherence, payer access, device reliability, and robust formulation performance.

 

Asthma: Large Patient Pool Sustains Rescue and Controller Inhaler Demand

Asthma remains one of the largest demand anchors for pulmonary drug delivery. WHO reported that asthma affected 363 million people globally in 2023 and caused 442,000 deaths. In the U.S., CDC reported 27.8 million people with current asthma in 2023, including 4.8 million children and 23.0 million adults. CDC also reported 11.75 million asthma attacks in 2023, showing why rescue inhalers, inhaled corticosteroids, spacer devices, and adherence-focused products remain central to asthma care.

The SABA category remains important because asthma attacks sustain rescue inhaler refills. At the same time, the market is moving beyond SABA-only rescue therapy. FDA approved Airsupra, an albuterol-budesonide inhalation aerosol, as an as-needed treatment for adults with asthma. FDA described it as the first U.S.-approved inhaled corticosteroid and short-acting beta agonist combination, creating a new commercial direction where rescue therapy also carries anti-inflammatory treatment value.

 

Mortality Burden and New Nebulized Therapy Strengthen the Maintenance Market

COPD is the second major volume pillar for pulmonary delivery systems. WHO reported that COPD caused 3.4 million deaths in 2023, making it the third leading cause of death worldwide. In the U.S., CDC has reported that nearly 16 million adults have COPD, while NCHS reported diagnosed COPD prevalence of 3.8% among adults in 2023. This disease base drives demand for LABA/LAMA therapies, ICS/LABA combinations, single-inhaler triple therapy, nebulized bronchodilators, homecare respiratory products, and maintenance refills.

The COPD market also gained a fresh launch signal in June 2024 when FDA approved Ohtuvayre, ensifentrine, for maintenance treatment of COPD in adults. Verona Pharma reported Q1 2025 Ohtuvayre net sales of USD 71.3 million and about 25,000 prescriptions filled during the quarter. Merck later agreed to acquire Verona Pharma for about USD 10 billion, showing that differentiated inhaled COPD products can attract major strategic interest.

 

Drug-Class Commercial Signals: Advanced Inhaled Classes Capture Higher Value

The market is not solely defined by prescription volumes, as value is increasingly concentrated in advanced inhaled therapies and specialty respiratory products. GSK reported Trelegy sales of approximately GBP 3.0 billion in 2025, reflecting 13% growth at constant exchange rates and reinforcing the commercial strength of single-inhaler triple therapy. AstraZeneca reported Symbicort 2025 revenue of USD 2.885 billion, indicating sustained relevance of ICS/LABA combinations despite generic erosion.

Specialty inhaled therapies contribute an additional layer of value creation. United Therapeutics reported total Tyvaso revenue of USD 1.878 billion in 2025, supported by adoption across pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Insmed reported ARIKAYCE 2025 revenue of USD 433.8 million, demonstrating that inhaled antibiotic therapies can establish durable specialty franchises when targeted to defined pulmonary infections.

 

Cystic Fibrosis: Smaller Population, Higher Treatment Intensity

Cystic fibrosis represents a smaller patient population than asthma or COPD, but remains a high-value segment for pulmonary drug delivery systems. The Cystic Fibrosis Foundation reports nearly 40,000 children and adults living with CF in the United States and approximately 105,000 diagnosed patients across 94 countries. In the U.S., around 1,000 new cases are diagnosed annually, with approximately 60% of patients aged 18 years or older.

This patient population supports sustained use of nebulized therapies, inhaled antibiotics, mucus clearance agents, and portable inhalation delivery systems. TOBI Podhaler, a tobramycin inhalation powder, is an approved therapy for cystic fibrosis patients with Pseudomonas aeruginosa infection, reinforcing inhaled antibiotics as a clearly defined specialty segment within CF management.

 

Bronchiectasis: Diagnosed Patient Pool Creates a New Specialty Respiratory Opportunity

Bronchiectasis is becoming more visible as a treatable commercial respiratory market. The American Lung Association estimates that bronchiectasis affects 350,000 to 500,000 adults in the U.S. Insmed has stated that about 500,000 U.S. patients are diagnosed with non-cystic fibrosis bronchiectasis, alongside about 600,000 diagnosed patients in the EU5 and 150,000 in Japan.

The product landscape changed in 2025 when FDA approved Brinsupri, brensocatib, as the first treatment for non-cystic fibrosis bronchiectasis in adults and children aged 12 years and older. Although Brinsupri is oral rather than inhaled, its approval validates bronchiectasis as a commercial respiratory category and may increase demand for complementary nebulized therapies, inhaled antibiotics, airway-clearance devices, and future inhaled bronchiectasis products.

 

PAH and PH-ILD: Dry Powder Treprostinil Builds a Premium Segment

Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease create one of the clearest premium opportunities for dry powder inhalers. Liquidia received FDA approval for YUTREPIA, treprostinil inhalation powder, in May 2025 for adults with PAH and PH-ILD. The company scheduled first commercial shipment in June 2025, adding competition to the inhaled treprostinil segment.

This category is commercially attractive because it combines specialty pricing, chronic use, specialty pharmacy distribution, and device-driven differentiation. Liquidia has cited more than 105,000 PAH and PH-ILD patients in the U.S., supporting a defined addressable base for inhaled prostacyclin products.

 

Diabetes: Inhaled Insulin Expands Pulmonary Delivery Beyond Lung Disease

Diabetes extends the relevance of pulmonary drug delivery beyond traditional respiratory applications. According to the World Health Organization, the global diabetic population increased from 200 million in 1990 to 830 million in 2022. In the United States, the CDC estimated 40.1 million individuals living with diagnosed or undiagnosed diabetes in 2023, including approximately 2.1 million diagnosed with type 1 diabetes.

Afrezza is notable as it utilizes pulmonary delivery for rapid-acting mealtime insulin rather than respiratory treatment. In May 2026, MannKind announced FDA approval of Afrezza for pediatric and adolescent patients aged 6 years and older with type 1 or type 2 diabetes. This approval reinforces the role of inhalation-based delivery in selected systemic therapies where rapid pharmacologic onset, needle-free administration, and episodic dosing provide clinical and commercial value.

 

Neurology: Parkinson’s OFF Episodes Support Episodic Inhaled Therapy

Neurology represents a smaller but clinically relevant opportunity for pulmonary drug delivery. The Parkinson’s Foundation estimates that approximately 1.1 million people in the United States are living with Parkinson’s disease, with nearly 90,000 new diagnoses annually, while more than 10 million individuals are affected globally. The WHO has also reported that Parkinson’s disease prevalence has doubled over the past 25 years.

Inbrija, an inhaled levodopa powder, is approved for the intermittent treatment of OFF episodes in patients with Parkinson’s disease receiving carbidopa/levodopa. Its clinical use demonstrates the feasibility of pulmonary delivery in addressing episodic neurological symptoms where rapid onset of action, ease of administration, and rescue dosing capability are important considerations.

 

Infectious Diseases: Inhaled Antibiotics Target Difficult Lung Infections

Infectious lung disease represents a smaller but clinically well-defined application area. According to the CDC 2022 Emerging Infections Program pulmonary nontuberculous mycobacteria report, confirmed incident pulmonary NTM cases were 4.6 per 100,000 population in EIP areas, while confirmed prevalent cases were 2.3 per 100,000 population. These infections commonly occur in patients with underlying chronic lung disease, supporting a rational role for targeted inhaled anti-infective therapies.

ARIKAYCE provides the strongest approved-product validation in this segment. It is an amikacin liposome inhalation suspension indicated for refractory Mycobacterium avium complex lung disease in adults with limited or no alternative treatment options. Its commercial performance demonstrates that inhaled antibiotic therapies can extend beyond niche hospital use when directed toward clearly defined chronic pulmonary infections.

 

Route and Device Platforms: Inhalers Lead, Nebulizers Remain Essential, DPI Gains Momentum

Inhalers remain the core commercial segment of pulmonary drug delivery due to their dominance in large chronic respiratory indications. Metered-dose inhalers continue to play a key role in rescue therapy and fixed-dose combination regimens, while dry powder inhalers are increasingly used in maintenance therapy and in indications such as triple therapy, pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, cystic fibrosis, inhaled insulin, and select neurological applications. Nebulizers remain clinically important in COPD, geriatric and pediatric care, severe exacerbations, bronchiectasis, cystic fibrosis, and Mycobacterium avium complex lung disease.

The device landscape is increasingly influenced by therapy economics. Triple therapy has enabled the development of high-value inhaler franchises, nebulized COPD therapies have demonstrated strong commercial uptake, and inhaled treprostinil dry powder formulations have established premium revenue streams in specialty care. Accordingly, pulmonary delivery is evolving into a platform-based market rather than a simple device substitution segment.

 

Prescription and Reimbursement: U.S. Payer Data Will Shape Access

Prescription and reimbursement data are becoming essential for market sizing. CMS Medicare Part D datasets track many drugs administered by patients themselves and provide visibility into spending, beneficiary count, dosage units, and utilization. MedPAC reported that Part D covered more than 51 million Medicare beneficiaries in 2023, while KFF reported that 54.8 million Medicare beneficiaries were enrolled in Part D plans in 2025.

For U.S. market modelling, the most useful indicators include spending by drug, beneficiary count, average spending per dosage unit, claims per patient, formulary access, prior authorization status, generic substitution, and out-of-pocket exposure. These measures are especially relevant for triple therapy, inhaled PAH products, inhaled antibiotics, and inhaled insulin.

 

Environmental Reformulation: Low-GWP Inhalers Create a Renewal Cycle

The environmental transition is becoming a major renewal driver for pressurized metered-dose inhalers. pMDIs depend on propellants, and the shift toward lower global-warming-potential alternatives is pushing reformulation, device testing, canister and valve redesign, and manufacturing investment. AstraZeneca received European regulatory support in 2025 for an eco-friendly version of its Trixeo Aerosphere/Breztri Aerosphere COPD inhaler using a next-generation propellant reported to have 99.9% lower global warming potential than conventional propellants.

This transition creates an opportunity for companies with pMDI engineering, propellant-transition capability, fill-finish capacity, and regulatory experience. It also gives dry powder and soft mist platforms a stronger position where health systems seek lower-carbon options without compromising treatment access.

 

Pipeline Direction: High-Payload DPI, RNA, Biologics, and Systemic Delivery Expand the Market

Pipeline development is increasingly focused on high-payload formulations and advanced pulmonary delivery systems. Aptar’s Orbital DPI platform is positioned to support high-capacity inhalation delivery, while broader industry R&D is expanding into inhaled RNA therapeutics, biologics, peptides, GLP-1–based approaches, nanocarrier systems, antivirals, and localized lung cancer treatments.

Near-term pipeline activity is increasingly defined by targeted development rather than broad exploratory innovation. Inhalation therapy demonstrates the strongest clinical rationale where it enables deep-lung delivery in pulmonary arterial hypertension and PH-ILD, localized antibiotic delivery in chronic respiratory infections, high-payload dry powder formulations for specialty indications, and rapid systemic absorption for selected episodic disease settings.

 

Pharma, Specialty Biotech, Device Platforms, and CDMOs Compete Together

The competitive landscape is structured across four key segments. Large pharmaceutical companies compete through established respiratory franchises, triple-therapy combinations, biologic-adjacent respiratory products, low-GWP reformulations, and device lifecycle management strategies. Specialty companies focus on inhaled antibiotics, pulmonary arterial hypertension dry powder therapies, inhaled insulin, and neurology rescue treatments. Device-platform manufacturers compete across dry powder inhaler systems, pressurized metered-dose inhaler components, nebulizers, soft mist devices, smart inhaler sensors, and propellant transition solutions. CDMOs and formulation specialists participate through inhalation formulation development, sterile nebulized solutions, powder engineering, and combination product manufacturing.

Recent transaction activity underscores the strategic value of differentiated pulmonary assets. Merck’s approximately USD 10 billion acquisition agreement for Verona Pharma, driven by Ohtuvayre, highlights the premium valuation assigned to inhaled therapies with established launch performance and expansion potential.

 

North America Leads, Europe Pushes Sustainability, Asia Pacific Adds Volume

North America remains the leading region, supported by FDA-approved specialty inhaled therapies, Medicare Part D reimbursement visibility, a well-established specialty pharmacy network, and widespread adoption of premium respiratory brands. Europe continues to represent a structurally important market due to mature prescribing practices, public health emphasis on inhaler sustainability, and regulatory support for lower-carbon respiratory solutions. Asia Pacific is expected to represent the largest future volume opportunity, driven by a high respiratory disease burden, urban air pollution exposure, improving diagnostic rates, and expanding access to maintenance inhaled therapies.

Emerging markets are expected to remain highly price-sensitive, with growth dependent on access to affordable generic inhalers, availability of nebulization infrastructure, patient education and training, reimbursement expansion, and improved diagnosis of asthma, COPD, and chronic respiratory infections.

 

Strategic Outlook: Value Growth Will Come from Specialty Inhaled Products and Platform Control

The Pulmonary Drug Delivery Systems Market will continue to be anchored by asthma and chronic obstructive pulmonary disease, while higher-value growth is expected from specialty inhaled therapies, including PAH and PH-ILD dry powders, inhaled antibiotics, inhaled insulin, episodic neurology therapies, low-GWP pressurized metered-dose inhaler reformulations, smart inhaler adherence technologies, and high-payload dry powder inhaler platforms. The most competitively positioned companies will be those that integrate respiratory franchise strength with drug-device engineering, scalable inhalation manufacturing, payer access capabilities, and pipeline assets leveraging the lung for both local and systemic delivery.

The market is evolving in two parallel directions. High-volume categories such as SABA, ICS, LABA/LAMA, ICS/LABA, and triple therapy will sustain the core market, while specialty segments including inhaled antibiotics, pulmonary hypertension therapies, mucolytics, inhaled insulin, and neurology rescue powders will drive incremental value creation. Competitive advantage will increasingly depend not on device capability alone, but on integrated control across molecule design, formulation strategy, delivery systems, reimbursement alignment, and patient convenience.

 

Pulmonary Drug Delivery Systems Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 58.7 Billion
Revenue Forecast in 2032	USD 95.5 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Route of Administration/Delivery Platform, By Drug Class, By Application, By End User, By Geography
By Route of Administration/Delivery Platform	Inhalers, Metered-Dose Inhalers, Dry Powder Inhalers, Nebulizers, Soft Mist Inhalers
By Drug Class	SABA, ICS, LABA/LAMA, ICS/LABA, ICS/LABA/LAMA, Inhaled Antibiotics, Inhaled Pulmonary Hypertension Drugs, Mucolytics & Hypertonic Saline, Systemic Inhaled Therapies
By Application	Asthma, COPD, Cystic Fibrosis, Bronchiectasis, Pulmonary Arterial Hypertension, Pulmonary Hypertension Associated with ILD, Diabetes, Neurology, Infectious Diseases
By End User	Hospitals, Homecare Settings, Retail Pharmacies & Online Pharmacies, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Rising prevalence of chronic respiratory conditions - Strong digital innovation in inhaler platforms - Regulatory push for adherence and precision dosing
Customization Option	Available upon request